Jinling Pharmaceutical Stock Forum

A year ago, overconfidence in the market led to a significant drop in share price compared to the EPS decline. Despite recent downturns, the stock has seen a 2% annual return over five years. However, Jinling Pharmaceutical's investment analysis reveals 3 warning signs, one of which is significant.

Despite Jinling's high profit retention, the low return rate could restrain growth. Its performance concerning against industry earnings trend. Independent due diligence is advised.